CTLA4 and neoplasm: Therefore, the application of monoclonal antibody to block CTLA-4 can relieve its inhibitory effects on T cells, reactivate T cell proliferation and differentiation into cytotoxic T lymphocytes (CTLs), thereby exerting anti-tumor immune effects (Fig. 2).